Professor of Neurology, Indiana University
Neurology
Dr. Martin R. Farlow, MD
|
|
Give Review
Martin Farlow practices Neurology. He studied medicine at Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care He received awards:"America's Top Doctors" and "Indianapolis Monthly". Martin Farlow is a published doctor and has 63 publications published. The lastest was: 'Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis.' Martin R. Farlow, MD is registered with Medicare and accepts Medicare payments.
Publications
- Quality Improvement in Skilled Nursing Facilities for Residents With Alzheimer's Disease.
- Genetic variants associated with susceptibility to psychosis in late-onset Alzheimer's Disease families.
- GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's Disease implicates microglial activation gene IL1RAP.
- Early behavioural changes in familial Alzheimer's Disease in the Dominantly Inherited Alzheimer Network.
- Protective variant for hippocampal atrophy identified by whole exome sequencing.
- Factors associated with the onset and persistence of post-lumbar puncture Headache.
- Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults.
- Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.
- Rarity of the Alzheimer Disease-Protective APP A673T Variant in the United States.
- Evaluating High-Dose Rivastigmine Patch in Severe Alzheimer's Disease: Analyses with Concomitant Memantine Usage as a Factor.
- A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzhei...
- Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease: A Genome-Wide Association Study.
- FASTKD2 is associated with memory and hippocampal structure in older adults.
- The Role of Choroid Plexus In IVIG-induced Beta-Amyloid Clearance.
- Age-Specific Incidence Rates for Dementia and Alzheimer Disease in NIA-LOAD/NCRAD and EFIGA Families: National Institute on Aging Genetics Initiative for Late-Onset Al...
- Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial.
- Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively Normal subjects.
- A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia.
- Immunotherapy for Alzheimer's Disease.
- Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics.
- A phase 3 trial of semagacestat for treatment of Alzheimer's Disease.
- Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment.
- Altered Default Mode Network Connectivity in Older Adults with Cognitive Complaints and Amnestic Mild Cognitive Impairment.
- High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines.
- Phenotypic variability in three families with valosin-containing protein mutation.
- Connecting research discovery with care delivery in Dementia: the development of the Indianapolis Discovery Network for Dementia.
- Increased β-amyloid deposition in Tg-SWDI transgenic mouse Brain following in vivo lead exposure.
- Safety and biomarker effects of solanezumab in patients with Alzheimer's Disease.
- Human Anti-prion Antibodies Block Prion Peptide Fibril Formation and NeuroToxicity.
- Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's Disease.
- Temporoparietal hypometabolism in frontotemporal lobar Degeneration and associated imaging diagnostic errors.
- Rivastigmine transdermal patch and capsule in Alzheimer's Disease: influence of Disease stage on response to therapy.
- Validation of consensus panel diagnosis in Dementia.
- Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's Disease: A 24-week, randomized, double...
- Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's Disease.
- Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer Disease.
- Correlation of clinical features with argyrophilic grains at autopsy.
- IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced Brain damage in neonatal rats.
- Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer Disease.
- Randomized clinical trial results for donepezil in Alzheimer's Disease: is the treatment glass half full or half empty?
- Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's Disease.
- Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
- Depressed mood in informal caregivers of individuals with mild cognitive impairment.
- Effective pharmacologic management of Alzheimer's Disease.
- Use of antidementia agents in vascular dementia: beyond Alzheimer Disease.
- Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with Normal cognition.
- Do cholinergic therapies have Disease-modifying effects in Alzheimer's Disease?
- Recommendations for best practices in the treatment of Alzheimer's Disease in managed care.
- Caffeic acid phenethyl ester possesses potent cardioprotective effects in a rabbit model of acute myocardial ischemia-reperfusion injury.
- Safety and acceptability of the research lumbar puncture.
- Combination drug therapies for AD: progress is slow, but we must keep trying.
- Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's Disease.
- Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.
- NMDA receptor antagonists. A new therapeutic approach for Alzheimer's Disease.
- On the horizon: pathways for drug development in Alzheimer's Disease.
- Update on rivastigmine.
- A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's Disease.
- Cerebral hypometabolism and grey matter density in MAPT intron 10 +3 mutation carriers.
- Language impairment in Alzheimer's Disease and benefits of acetylcholinesterase inhibitors.
- Comparing clinical profiles in Alzheimer's Disease and Parkinson's Disease dementia.
- Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel.
- Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis.
Schools
Indiana University School Of Medicine
Ind University Hospital
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Anterior Horn Disease
- Ataxia
- Brain Aneurysm
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- America's Top Doctors
- Indianapolis Monthly
Education
-
Indiana University School of Medicine
Drug Facts
| NPI NUMBER | 1508880022 | |
| NPPES Provider LastName | FARLOW | |
| NPPES Provider FirstName | MARTIN | |
| NPPES Provider ZIPCode | 462025149 | |
| NPPES Provider State | IN | |
| Specialty Description | Neurology | |
| Total Claim Count | 2482.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 0.6 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508880022 |
| Last Name Of The Provider | FARLOW |
| First Name Of The Provider | MARTIN |
| View All |
Similar Doctors
|
|
Dr. David Mattson, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Riley J. Snook, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Monica E. Mazda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew E. Bain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cynthia K. McGarvey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald D. Strobel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann Marie M. Hake, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward C. Daly, MD |
|
|
Dr. Omkar N. Markand, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Karen L. Roos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wesley B. Wong, MD |
|
|
Dr. Oldrich J. Kolar, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rohit R. Das, MD |
|
|
Dr. Shafer Z. Kurshuk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul Bustion Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristi K. George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Salvatore Spina, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hadi S. Tolooi, MD |